Oscient, Pfizer enter agreement for Factive tablets in Mexico

By Lisa Kerner

Erie, Pa., Feb. 7 - Oscient Pharmaceuticals Corp. said it has sublicensed the commercialization rights to Factive (gemifloxacin mesylate) tablets in Mexico to Pfizer, SA de CV (Pfizer Mexico).

Pfizer Mexico has agreed to pay Oscient an up-front payment, milestones for attaining certain regulatory and sales goals, and royalties on future sales, according to a company news release.

Pfizer will work with the regulatory agency in Mexico to facilitate the marketing approval of Factive. Oscient will be the sole provider of product to Pfizer Mexico, the release stated.

Specific financial terms were not disclosed.

Factive is approved in the United States for the treatment of community-acquired pneumonia of mild to moderate severity and acute bacterial exacerbations of chronic bronchitis.

Oscient is a Waltham, Mass.-based biopharmaceutical company.

Pfizer, based in New York, is a global pharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.